Maternal supplementation with LGG reduces vaccine-specific immune responses in infants at high-risk of developing allergic disease
Paul V Licciardi, Intan H Ismail, Anne Balloch, Milton Mui, Edwin Hoe, Karen Lamb, Mimi LK Tang
Frontiers in Immunology | FRONTIERS MEDIA SA | Published : 2013
The studies were funded by grants from the Jack Brockhoff Foundation, the Murdoch Childrens Research Institute, the Australian National Health and Medical Research Council (NHMRC) and the Ilhan Food Allergy Foundation. This study was supported in part by the Victorian Government's Operational Infrastructure Support Program. Paul V. Licciardi is the recipient of a NHMRC Early Career Fellowship. Intan Ismail was supported by a scholarship from the Ministry of Higher Education, Malaysia and Universiti Putra Malaysia. LGG and placebo capsules were manufactured and supplied by Dicofarm Ltd. (Roma, Italy). The HbO-HA antigen for the Hib studies was obtained through the NIH Biodefense and Emerging Infections Research Repository, NIAID, NIH: H. influenzae type b oligosaccharide-Human Serum Albumin Conjugate (Hbo-HA Antigen), NR-122268. We thank Lam Kwang-Yang and Natalie Wei Ling Yeong for their help with the total IgG assays. We are grateful to the participating families and the midwifery staff of the Mercy Hospital for Women for their cooperation, to Michael Permezel, Kay Hynes, Christine Plover, Maggie Flood, Christine Axelrad, Sally Moore, Val Bryant, and Noel Cranswick for their assistance in the conduct of this trial, to Frances Oppedisano for her assistance with immunological studies and to John Su for advice regarding eczema assessment.